Cargando…
Qingfei Xiaoyan Wan alleviates asthma through multi-target network regulation
BACKGROUND: Qingfei Xiaoyan Wan (QFXY), a traditional Chinese formula, is widely used for relieving cough, asthma, upper respiratory tract infection, bronchitis, pneumonia, and etc. in clinic. Comparing with other anti-asthma drugs, it is characterised with moderate and persistent efficacy as well a...
Autores principales: | Zhao, Zhenying, Miao, Yingbo, Pan, Pengwei, Cheng, Binfeng, Bai, Gang, Wu, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765495/ https://www.ncbi.nlm.nih.gov/pubmed/23919426 http://dx.doi.org/10.1186/1472-6882-13-206 |
Ejemplares similares
-
Searching for Synergistic Bronchodilators and Novel Therapeutic Regimens for Chronic Lung Diseases from a Traditional Chinese Medicine, Qingfei Xiaoyan Wan
por: Hou, Yuanyuan, et al.
Publicado: (2014) -
Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates Pseudomonas aeruginosa–induced acute lung inflammation by regulation of PI3K/AKT and Ras/MAPK pathways
por: Hou, Yuanyuan, et al.
Publicado: (2016) -
Systematic identification of the interventional mechanism of Qingfei Xiaoyan Wan (QFXYW) in treatment of the cytokine storm in acute lung injury using transcriptomics-based system pharmacological analyses
por: Hou, Jing-Yi, et al.
Publicado: (2022) -
Histone deacetylation of memory T lymphocytes by You-Gui-Wan alleviates allergen-induced eosinophilic airway inflammation in asthma
por: Zhang, Hong Ping, et al.
Publicado: (2015) -
Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo
por: Deng, Wei, et al.
Publicado: (2020)